COVID-19 vaccine strategies must focus on severe disease and global equity

The Lancet
Jan 22, 2022 Volume 399 Number 10322 p335-410
https://www.thelancet.com/journals/lancet/issue/current

 

Viewpoint
COVID-19 vaccine strategies must focus on severe disease and global equity
Peter B McIntyre, et al.
[Excerpt]
Global COVID-19 vaccine strategies in 2022
:: COVID-19 vaccine strategies should continue to prioritise prevention of severe disease
:: Variants of concern such as delta and potentially omicron render strategies aimed at SARS-CoV-2 transmission unlikely to have more than a short-term effect on preventing severe COVID-19
:: In countries with a high prevalence of previous infection and a low proportion of the population being older than 60 years prioritising delivery of the first dose will have the greatest effect on preventing severe COVID-19
:: In countries with a low prevalence of previous infection and a high proportion of the population being older than 60 years, protection against severe disease in adults requires at least two doses
:: In people who are severely immunocompromised or older than 60 years, evidence supports booster doses of mRNA or adenoviral vector vaccines to prevent severe disease; booster doses for all adults could compromise timely global availability of first doses